In 2021, the FDA approved Opdivo, a programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitor, for the initial treatment of patients with advanced gastric cancer [4]. Here, PDCD1 is linked to gastric cancer.